Imipenem/Cilastatin
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Imipenem/Cilastatin | 250-500mg IV Q12H | Administer Post-HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 299/358 | 20-70 | 1 | 4 | 13-21 | 0.17-0.3 | 68-84/41-65 | 21-90/38-63 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Berman S, Sugihara J, Nakamura J et al. Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis. The American journal of medicine 1985; 78(6A), 113-6.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01598, http://www.drugbank.ca/drugs/DB01597
- Gibson T, Demetriades J, Bland J. Imipenem/Cilastatin: Pharmacokinetic Profile in Renal Insufficiency. Medicine 1985; 78(Suppl 6A), 54-61.
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Konishi K, Suzuki H, Saruta T et al. Removal of Imipenem and Cilastatin by Hemodialysis in Patients with End-Stage Renal Failure. Antimicrobial agents and chemotherapy 1991; 35(8), 1616-22.
- Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
- Verpooten G, Verbist L, Buntinx A, Entwistle L, Jones K, De Broe, M. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. British journal of clinical pharmacology 1984; 18(2), 183-93.